Dengue, RSV, Mpox, Shigella & More | June 2025 Vaccine Breakthroughs 🌍💉đź§
This week’s edition of Vaccine Research Updates brings you a powerful roundup of global immunization advances from Phase 3 trials to regulatory green lights. Whether you’re in biotech, public health, or clinical research, these headlines signal what’s next in vaccine development:
🦟 MSD begins its Phase 3 MOBILIZE-1 trial for dengue vaccine V181
🌍 GSK hands off its low-cost Shigella vaccine to Bharat Biotech
🧒 Bavarian Nordic launches a Phase 3 pediatric trial for its CHIKV VLP vaccine in children aged 2 to 11
đź’‰ Moderna wins FDA approval to extend its RSV vaccine, mRNA-1345
🔬 Clover Biopharma kicks off Phase 1 trials for two combo vaccines targeting RSV, hMPV, and PIV3
🇪🇺 GeoVax secures EMA support to advance directly to Phase 3 for its GEO-MVA Mpox and smallpox vaccine
📢 Stay Ahead in Vaccine Research!
âś… Like, share, and subscribe for weekly updates on vaccine research
#VaccineResearch #DengueVaccine #RSVPrevention #MpoxVaccine #ShigellaVaccine #Moderna #GeoVax #BharatBiotech #ClinicalTrials #InfectiousDiseases #PublicHealth #LucidQuest #LQVentures #GlobalHealth #BiotechNews #PediatricVaccines #AIinHealthcare #FDAApproval #EMA #VaccineDevelopment #CloverBiopharma #BavarianNordic #Merck #CEPI